

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62227 A2

(51) International Patent Classification⁷: A61K 9/12, 31/46

(21) International Application Number: PCT/EP01/01833

(22) International Filing Date: 19 February 2001 (19.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2000A000312 22 February 2000 (22.02.2000) IT

(71) Applicant (for all designated States except US): CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEWIS, David [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). GANDERTON, David [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). MEAKIN, Brian [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). BRAMBILLA, Gaetano [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). FERRARIS, Alessandra [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).

(74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milan (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/62227 A2

(54) Title: FORMULATIONS CONTAINING AN ANTICHOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

(57) Abstract: Formulations for the administration through pressurized metered dose aerosol inhalers containing an anticholinergic drug in solution in a hydrofluorocarbon propellant, a cosolvent and a low volatility component, and the use thereof in chronic obstructive pulmonary disease.

FORMULATIONS CONTAINING AN ANTICHOLINERGIC DRUG
FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE

The present invention relates to formulations for administration through pressurized metered dose inhalers containing a quaternary ammonium salt with anticholinergic action in solution in a hydrofluorocarbon propellant, a cosolvent and a low volatility component.

5 More particularly, the invention relates to formulations containing ipratropium bromide in solution, in which the concentration of active ingredient corresponds to single doses ranging from 80 to 320 µg and the amount of respirable particles is directly related to the dose itself. "Single dose" means the amount of active ingredient delivered by a single actuation

10 of the inhaler.

The formulations of the invention can be useful for the treatment of any respiratory disease and in particular for the treatment of the chronic obstructive pulmonary disease.

The term chronic obstructive pulmonary disease (COPD) refers to a

15 spectrum of diseases such as chronic bronchitis, asthma and lung emphysema, characterized by bronchospasm, cough, hypersecretion and dyspnea which are more and more frequent also due to tabagism as well as an increase of atmospheric pollution. Such disease has social relevance in that it involves repeated, expensive treatments.

20 Anticholinergic quaternary ammonium salts, such as oxitropium bromide, tiotropium bromide and ipratropium bromide, are usually prescribed in the form of inhalatory formulations, for patients suffering from said disease, due to their bronchodilating, antisecretive and bronchospasm-preventive actions.

Said drugs, particularly ipratropium bromide, induce less prompt bronchodilation than conventional β_2 -agonists, but provide greater peak response and longer duration of action. Said characteristics make them particularly suitable for the chronic treatment rather than the acute one

5 (Ferguson G. et al. *N Engl J Med* 1993, 328, 1017-1022).

Although the single optimal dose for the administration of nebulized ipratropium bromide in the treatment of COPD has been established to be 0.4 mg (Gross NJ et al *Am Rev Respir Dis* 1989, 139, 1188-1191), the dosage via pressurized metered dose inhalers has not yet been univocally established.

10 Some authors (Ferguson G. et al, *passim*) have however suggested that treatment of said disease could benefit from use of higher doses than recommended ones (54-109 μ g). Recent studies (Ikeda A et al. *Thorax* 1996, 51, 48-53; Shivaram U et al. *Resp Med* 1997, 91, 327-334; Wood F et al. *Amer J Resp Crit Care Med* 1999, 159, A 523) have demonstrated that the

15 administration of single doses ranging from 80 to 320 μ g is beneficial for the improvement in lung function, maximal workload and oxygen consumption.

Wood et al also observed for doses of at least 160 μ g a longer duration of action, up to 12 hours: such prolonged effect would allow for a bis in die (b.i.d.) (twice a day) administration with evident advantages in terms of

20 patient compliance.

The formulations currently available on the market in the form of metered dose aerosols in chlorofluorocarbons (Freon 11 and Freon 12) suspensions are able of delivering single doses of 20 or 40 μ g and the recommended posology envisions the administration of 1-2 shots 3-4 times a

25 day. Therefore, an increase of the frequency of administration to 4-6 times a day would be necessary to guarantee a higher daily dosage regimen, thus adversely affecting the patient compliance.

On the other hand, the effectiveness of an aerosol device, particularly

a pressurized metered dose aerosol, is a function of the dose deposited in the peripheral tract of the pulmonary tree, that is, in turn mainly affected by the particle size distribution. The particle size is quantified by measuring a characteristic equivalent sphere diameter, known as median aerodynamic diameter (MAD). Particles having a MAD ranging from 0.8 to 5 microns (μm) are usually considered respirable, i.e. capable of being deposited into the lower airways. It has also been established that, in the case of anticholinergic drugs for use in obstructive pulmonary diseases, the optimal particle size should be approximately 3 μm (Zanen P et al. *Int. J. Pharm.* 1995, 114, 111-115; *Thorax* 1996, 51, 977-980).

In the suspension formulations, the size distribution of the delivered particles almost exclusively depends on the particle size distribution of the suspended particles, and hence on the process used for preparing them (milling or precipitation). Any kind of adjustments of the particle size of the delivered aerosol can be carried out by those skilled in the art, by suitably changing amounts and types of excipients, surface tension of the propellant, size of the metering chamber and diameter of the actuator orifice. The preparation of suspension formulations at higher concentrations of drugs aimed at delivering higher single doses could however involve problems intrinsically difficult to be solved. Under high concentration conditions, the suspended particles could, indeed, give rise to aggregation, particularly during storage, so to an increment of the size of particles. Larger size particles deposit more quickly and can give rise to the formation of compacted and fuse agglomerates (cakes) which, in turn may impair the possibility of re-suspending the product by simple agitation. Such drawback, could jeopardize both physical stability and therapeutic efficacy of the respective formulations; moreover, even after aerosolization, said cakes could turn out to be hard to be re-dispersed, so they will deposit mainly on

the oropharynx tract, to the detriment of the fraction deposited on the peripheral respiratory tract (respirable fraction).

It is known that the chlorofluorocarbon propellants such as Freon 11 and Freon 12, which for many years have been the preferred propellants used 5 in the aerosols, are being phased out and also their use in medicinal formulations, although temporarily exempted, will be banished.

Hydrofluoroalkanes (HFAs) and in particular 1,1,1,2-tetrafluoro-ethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates as substitutes for CFCs.

10 A number of documents concerning the preparation of HFA formulations of ipratropium bromide are disclosed in the prior art, for example WO 91/11495, WO 91/11496 (Boehringer), WO 93/05765 (Fisons), WO 96/19168 (Astra) and WO 98/34595 (Jago); these examples, however, relate to suspension formulations in which the active ingredient 15 concentrations (0.08-0.1% by weight) correspond to single doses of 20-50 µg; furthermore, no data concerning physical stability during storage are provided. In other documents (EP 513217, WO 92/00107, EP 587790, EP 588897, WO 94/21228, WO 94/21229, WO 98/34596, WO 98/24420), formulations containing ipratropium bromide are only cited but not 20 exemplified.

High-dosage suspension formulations in which CFCs are replaced with HFAs would nevertheless exhibit the same pitfalls in term of physical stability and therapeutical efficacy as mentioned above; moreover, in the case of anticholinergic quaternary ammonium salts such as ipratropium 25 bromide, the possibility of preparing formulations of adequate physical stability during storage would further be compromised or even prevented by the partial solubility of said active ingredient in HFA (Brambilla et al. *Int J Pharm* 1999, 186, 53-61); in fact, the size of the suspended particles could

grow during storage as a consequence of the partial or total recrystallization of the small amount of dissolved solute, thus worsening the problems deriving from the lack of steady particle size distribution.

In this scenario, solution compositions should unavoidably been used.

- 5 Said compositions provide a number of advantages in that they are easier to be prepared and could allow to avoid the physical stability problems potentially linked to the high dosage suspension formulations. However, even solution formulation are not rid of potential drawbacks as they can give rise, for instance, to more severe problems of chemical instability.
- 10 Furthermore, since the suspended particles no longer contribute to the total volume, the problem of ensuring a direct relationship between increase in dosage and increase in the drug deposited at the therapeutical site (respiratory tract) is even more dramatic. The preparation of homogeneous solution formulations requires indeed the addition of cosolvents such as
- 15 ethanol which, due to their vapor pressure higher than the propellant, increase, proportionally to their concentration, the velocity of the aerosol droplets leaving the actuator orifice. The high velocity droplets extensively deposit into the oropharyngeal tract to the detriment of the dose which penetrates into the lower airways. The higher the dosage of the drug the
- 20 higher is the amount of cosolvent necessary to solubilise, and hence the lesser is the percentage of therapeutically effective droplets (respirable dose).

In consideration of the therapeutical requirements outlined above and problems thereof, it would be highly advantageous to provide solution formulations comprising an anticholinergic drug, such as ipratropium bromide to be used with pressurised metered dose inhalers, in which the active ingredient concentration corresponds to single doses ranging from 80 to 320 µg, characterized by adequate chemical stability for pharmaceutical

use and capable of providing, on actuation, an amount of respirable particles directly proportional to the delivered dose. Said formulations would turn out to be useful for the treatment of respiratory ailments such as chronic obstructive pulmonary disease.

5 The object of the present invention is to provide solution formulations comprising an anticholinergic quaternary ammonium salt selected from oxitropium bromide, tiotropium bromide and especially ipratropium bromide, to be used with pressurized metered dose inhalers for the treatment of COPD, said solutions being chemically stable and capable of:

10 i) delivering high single doses, of at least 60 µg and preferably 80 µg;
ii) provide an amount of respirable particles directly proportional to the delivered dose;
iii) allow b.i.d. administration with evident advantages in terms of patient compliance.

15 In the formulations of the invention, to make the transition from CFC formulations to HFA formulations easier, the respirable fraction can favorably correspond to that of the CFC suspension formulations presently available on the market.

According to a first embodiment of the invention, there is provided a
20 solution formulation comprising from 0.11% to 1.14% by weight of an anticholinergic quaternary ammonium salt and a carrier consisting of a hydrofluoroalkane propellant, a cosolvent and a low volatility component that also has solvent properties.

In a preferred embodiment the hydrofluoroalkane propellant is HFA
25 134a, the cosolvent is ethanol and the low volatility component is glycerol.

According to a more particular embodiment of the invention, there is provided a solution formulation comprising from 0.14% - 0.28% by weight of ipratropium bromide and a carrier consisting of HFA 134a as a propellant,

13% by weight of ethanol and 1% by weight of glycerol.

In WO 98/56349 the Applicant disclosed solution compositions for use in an aerosol inhaler, comprising an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a 5 low volatility component to increase the median aerodynamic diameter (MAD) of the aerosol particles on actuation of the inhaler; the examples concerning ipratropium bromide however refer to formulations in which the active ingredient concentrations corresponded to the usual single doses (20-40 µg). Said formulations proved to be pharmaceutically equivalent to the 10 presently marketed formulations, consisting of CFC suspensions (Ganderton D et al. J. Aerosol Med. 1999, 12, 119).

It has now been found that by using a low volatility component with suitable solvent power for the active ingredient, homogeneous solution formulations are obtained even in the presence of concentrations of an 15 anticholinergic quaternary ammonium salt comprised between 0.11% and 1.14% by weight (which equates to 0.11-1.14 g of active ingredient per 100 g of formulation). In particular, it is possible to prepare homogeneous solution formulations in the presence of 0.14% - 0.28% by weight ipratropium bromide corresponding to single doses ranging from 80 to 320 20 µg.

The use of a low volatility component allows to minimize the amount of cosolvent, in this case ethanol, added to the formulation and hence to avoid the negative effects on the respirable/therapeutically effective dose due to the increase of its relative percentage.

25 In the formulations of the invention, the median aerodynamic diameter (MAD) of the droplets remains substantially unchanged at increasing concentrations, therefore the respirable dose is directly related to the dose obtained on actuation of the inhaler. As a consequence, the increase in the

respirable fraction concentration remains steady. Contrary to what reported in the prior art (Dolovich M Aerosol Science and Technology 1995, 22, 392-399) it has in fact surprisingly been found that in the formulations of the invention the respirable fraction does not decrease as the single dose increases. Furthermore, by suitably adjusting the actuator orifice diameter, it is possible, as the delivered dose increases, to steadily increase the respirable dose so that this is also linearly related to the dose of the CFC suspension formulations presently available on the market. Said feature makes the formulations of the invention therapeutically preferable as they avoid possible problems related to a non-linear response, such as accumulation, greater side effects or *vice versa* less effective therapeutical action.

WO 94/13262 generically disclosed and claimed aerosol HFA solution formulations comprising 0.001%-2.5% of ipratropium bromide in the presence of ethanol as cosolvent and of small amounts of organic or inorganic acids. The specific examples however only relate to formulations with active ingredient concentrations (0.0187% -0.0748% by weight) corresponding to doses for single actuation ranging from 10 to 40 µg and containing 15% by weight of ethanol. Furthermore, organic or inorganic acids are used for ensuring higher chemical stability of the active ingredient, and not for solving the technical problem related with the preparation of high dosage formulations providing a respirable dose therapeutically effective and directly related to the concentration.

The Applicant has also proved that formulations prepared according to the teaching of said application, with high concentrations of ipratropium bromide, require the use of ethanol in remarkable percentages which significantly jeopardize the performances in terms of respirable fraction. It has been indeed demonstrated that, in solution formulation only consisting of HFA as a propellant and ethanol as a co-solvent, the amount of ethanol

necessary to solubilize ipratropium bromide in concentrations corresponding to single doses ranging from 80 to 160 µg is of at least about 19% by weight. On the other hand, formulations containing such a large amount of ethanol, of at least 19% by weight, give rise to a reduced respirable dose and a 5 decrease in the MAD.

The formulations of the invention can be prepared as described in WO 98/56349 and comprise a quaternary ammonium salt provided of anticholinergic action, such as oxitropium bromide, tiotropium bromide, ipratropium bromide in a concentration that, depending on the characteristics 10 of the active ingredient, ranges from 0.11% to 1.14% by weight and which, in turn, could give rise, by suitably adjusting the volume of the metering chamber, to single doses ranging from 60 to 640 µg. More preferably, the active ingredient is a quaternary ammonium salt provided with anticholinergic action in a concentration ranging from 0.12% to 0.56% by 15 weight.

Even more preferably, the active ingredient is ipratropium bromide in a concentration ranging from 0.14% to 0.28% by weight. According to the volume of the metering chamber, the formulation containing 0.14% ipratropium bromide can be used for delivering single doses of 80 and 160 20 µg, while that containing 0.28% for single doses of 160 and 320 µg. Advantageously, the low volatility component has a vapor pressure at 25°C not above 0.1 kPa, preferably not above 0.05 pKa. Particularly suitable for the use of the invention are glycols, in particular propylene glycol, polyethylene glycol and most preferably glycerol. However, the invention 25 also comprises all the substances, alone or in admixture, having similar vapor pressure characteristics and suitable solvent power for the active ingredients belonging to the anticholinergic quaternary ammonium salts. The composition preferably contains at least 0.2%, more preferably 1% by

weight of said component and anyway no more than 6%.

The cosolvent has advantageously higher polarity than the propellant and is preferably an alcohol, more preferably ethanol. In this case, the amount of cosolvent in the composition is below 19% by weight, preferably, 5 it does not exceed 15% by weight, more preferably it does not exceed 13% by weight.

All the percentages are expressed as gram per 100 g of formulation.

Preferred hydrofluoroalkane propellants are HFA 134a, HFA 227 or mixtures thereof.

10 The formulations of the invention are preferably stored in pressurized inhalers for aerosol, part or all of their inner metal surfaces being made of anodized aluminium, stainless steel or coated with an inert organic coating agent. It has, in fact, been observed that in this type of cans the active ingredient remains chemically stable during storage, even at concentrations 15 higher than 0.11% by weight. The inhalers can be equipped with any suitable conventional or unconventional dispensing valve, preferably a metered dose valve as well as any suitable conventional or unconventional metering chamber. Advantageously, the inhalers are equipped with an actuator with orifice diameter from 0.25 to 0.50 mm, preferably 0.3 mm and 20 with a metering chamber with a volume from 25 μ l to 100 μ l. However, the volume of metering chamber and the orifice diameter of the actuator will be suitably selected by the person skilled in order to deliver the desired single dose as well as to the best performances in term of respirable dose.

Finally, the invention relates to the use of said formulations in the 25 treatment of bronchopulmonary diseases, in particular chronic obstructive pulmonary disease.

Specific embodiments of the invention are described in detail in the following.

Example 1: Ipratropium bromide aerosol solution formulation in a carrier constituted of HFA 134a as a propellant, ethanol as a co-solvent and glycerol as a low volatility component

The aerosol formulations of the invention described below are 5 prepared according to the following method. The components necessary to the formulation are transferred into 12 ml aerosol cans in the following order: drug, low volatility component, absolute ethanol.

After crimping the valve onto the can, the propellant is added through the valve. The weight gain of the can after addition of each component is 10 recorded to evaluate the weight percentage of each component in the formulation.

Components	Amounts		Dose of a single actuation
	Per unit	mg	
		% by weight	μg
Ipratropium bromide	19.2-38.4	0.14-0.28	80 – 320
Absolute ethanol		13	-
Glycerol		1	-
HFA 134a q.s. to	13714	-	-

The aerodynamic particle size distribution of each tested formulation 15 was characterized using a Multistage Cascade Impactor according to the procedure described in European Pharmacopoeia 2nd edition, 1995, part V.5.9.1, pages 15-17. In this specific case, an Andersen Cascade Impactor (ACI) was used.

Results were obtained as a mean of 3-4 cans. For each device, 5-25 20 cumulative actuations were carried out after discarding the first 5.

Deposition of the drug on each ACI plate was determined by high

pressure liquid chromatography (HPLC). Mean metered dose was calculated from the cumulative deposition in the actuator and ACI (stages); mean delivered dose was calculated from the cumulative deposition in the ACI. Mean respirable dose (fine particle dose) was obtained from the deposition 5 on Stages 3 to filter corresponding to particles $\leq 4.7\mu\text{m}$, divided by the number of actuations per experiment.

MAD and associated GSD (standard geometric deviation) values were obtained from probit transformation of cumulative percent undersize - log (ACI effective cut-off particle size diameter) and linear regression analysis 10 of the resultant data, (Ph. Eur. Supp 1999).

The delivery characteristics of formulations containing increasing amounts of ipratropium bromide present in cans equipped with standard Bespack BK 360 actuators with 0.3 mm orifice diameter and a metering chamber volume of 50 μl are reported in Table 1. The use of a metering 15 chamber volume of 100 μl allows a 320 μg strength variant of the 160 μg formulation.

It can be observed that MAD is substantially unaffected by the active ingredient concentration, so that the amount of droplets with size lower than 4.7 μm (respirable dose) is linearly related to the nominal dose.

20 Only at a nominal dose of 320 μg , a slight decrease of the respirable fraction is observed.

Table 1: Performances of formulations containing as active ingredient ipratropium bromide at different concentrations, such as to give raise to the reported nominal doses.

Nominal Dose ⁽¹⁾ (μ g)	Metered dose ⁽²⁾ (μ g)	Delivered dose ⁽³⁾ (μ g)	Respirable dose ⁽⁴⁾ (μ g)	Respirable fraction ⁽⁵⁾ (%)	MAD (μ m)	GSD
20	20.6 ± 1.6	18.8 ± 1.6	6.8 ± 1.1	33.3 ± 3.8	2.4 ± 0.3	2.1 ± 0.8
40	42.2 ± 1.8	38.7 ± 1.9	11.7 ± 1.2	31.5 ± 3.8	2.2 ± 0.1	2.1 ± 0.1
80	78.5 ± 0.4	72.7 ± 0.6	23.3 ± 4.5	32.0 ± 6.1	2.7 ± 0.3	2.2 ± 0.1
160	161.1 ± 12.5	149.2 ± 10.7	45.2 ± 2.5	30.4 ± 3.5	2.5 ± 0.2	2.3 ± 0.1
320	321.4 ± 2.0	290.5 ± 1.9	73.2 ± 3.0	25.2 ± 1.2	2.9 ± 0.2	2.6 ± 0.1

5 (1) Nominal dose: theoretical dose per single actuation

(2) Metered dose: sum of the dose delivered through the device plus the active ingredient residue deposited on the device actuator.

(3) Delivered dose: amount of active particles deposited into the various ACI stages

0 (4) Respirable dose (fine particle dose): amount of active particles of size less than $4.7 \mu\text{m}$

(5) Respirable fraction (fine particle fraction): ratio between the delivered dose and the respirable dose.

Example 2: Ipratropium bromide aerosol solution formulation in HFA 134a as a propellant and ethanol as a co-solvent

Determination of the solubility of ipratropium bromide in ethanol

20.1±0.2mg of ipratropium bromide is weighed into Saint-Gobain aerosol bottles.

Increased volumes of absolute ethanol are added to the same aerosol bottle using a Gilson variable pipette.

A Bespak BK357 valve is crimped onto the same aerosol bottle. Shaking and ultra-sonication ensured a homogeneous solution was formed before a pre-determined mass of HFA 134a is filled through the valve.

5 The individual weight of ipratropium bromide, ethanol, and HFA134a addition is recorded using a four-figure analytical balance.

Final formulations have a total volume into cans having a volume of $12 \pm 0.3\text{ml}$ (20°C), corresponding to that of the standard aerosol cans. The components are expressed as percentages by weight of the total formulation. Visual appearance of all manufactured formulations is assessed using a 10 polarized light source immediately after preparation and again after 3 weeks storage at $4.0 \pm 0.4^\circ\text{C}$. Observations were further confirmed after 10 months storage at $4.0 \pm 0.4^\circ\text{C}$.

Ipratropium bromide is found to crystallise for the following ethanol levels (% by weight): 14.7, 15.0, 16.8, 17.2, 17.5, 17.9 while is found not to 15 crystallise for the following ethanol levels: 18.9, 19.2, 20.6, 21.0, 21.3, 22.2, 22.6, 23.0, 23.4, 24.5, 29.7, 38.9, 40.1.

Therefore about 19% by weight of ethanol is required to solubilise an amount of ipratropium bromide (0.14% by weight) which could give rise, by 20 suitably selecting the volume of the metering chamber, to single doses of 80 and 160 μg within a HFA 134a formulation.

The formula of the corresponding composition is reported below.

Components	Amount		
	Per unit	% by weight	Dose of a single actuation
	mg		μg
Ipratropium bromide	20.1	0.14	80-160
Absolute ethanol	2735	19	-
HFA 134a q.s. to	14397	-	-

Delivery performances of the HFA formulations corresponding to single nominal doses of 80 and 160 µg

The delivery characteristics of the formulation in cans equipped with standard Bespack BK 360 actuators with 0.3 mm orifice diameter and a 5 metering chamber volume of 50µl are reported in Table 2. The use of a metering chamber volume of 100µl allows a 160µg strength variant of the 80µg formulation.

The relevant parameters were determined as described in Example 1.

It can be observed that, the formulation containing an ethanol level of 10 19% by weight depresses the respirable dose ($\leq 4.7 \mu\text{m}$); it also reduces the MAD from 2.2 – 2.9 μm to 1.2 – 1.3 μm ; and increases the Geometric Standard Deviation (GSD) from 2.1 - 2.6 to 4.3 – 6.2.

Table 2: Performances of a the formulation without the low volatility 15 component containing as active ingredient ipratropium bromide corresponding to nominal doses of 80 and 160 µg.

Nominal Dose (µg)	Metered dose (µg)	Delivered dose (µg)	Respirable dose (µg)	Respirable fraction (%)	MAD (µm)	GSD
80	76.6 ± 1.6	70.0 ± 1.0	20.0 ± 1.3	28.7 ± 1.5	1.2 ± 0.1	4.3 ± 0.4
160	158.5 ± 2.0	144.2 ± 1.7	31.4 ± 1.3	21.8 ± 1.1	1.3 ± 0.2	6.2 ± 0.2

CLAIMS

1. A pharmaceutical formulation for use in a metered dose aerosol inhaler, comprising an active ingredient consisting of an anticholinergic 5 quaternary ammonium salt in solution in a mixture consisting of a hydrofluoroalkane propellant, a cosolvent and a low volatility component, wherein the concentration of the active ingredient ranges from 0.11% to 1.14% by weight and the single dose delivered on actuation ranges from 60 to 640 µg.
- 10 2. A formulation according to claim 1, in which the active ingredient is ipratropium bromide in concentrations ranging from 0.14 to 0.28 % by weight.
- 15 3. A formulation according to claims 1-2, in which the propellant is HFA 134a, the low volatility component is glycerol and the cosolvent is ethanol.
4. A formulation according to claims 1-3 in which the ethanol percentage is 13% by weight and that of glycerol is 1% by weight.
5. Pharmaceutical formulations according to claims 1-4 for use in pressurized metered dose aerosol inhalers in the treatment of 20 bronchopulmonary diseases, and in particular chronic obstructive pulmonary disease.
- 25 6. Compositions according to any one of claims 1-5 contained in metered dose aerosol inhalers having part or all of the inner metal surfaces made of anodized aluminium, stainless steel or coated with an inert organic coating agent.
7. A process for the preparation of pharmaceutical formulations according to claims 1-6 which consists in filling the components into the metered dose inhaler in the following order: active ingredient, low volatility

component, cosolvent and finally propellant through the valve.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62227 A3

(51) International Patent Classification⁷: A61K 9/12, 31/46

(74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milan (IT).

(21) International Application Number: PCT/EP01/01833

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 19 February 2001 (19.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
MI2000A000312 22 February 2000 (22.02.2000) IT

(71) Applicant (*for all designated States except US*): CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).

Published:

— with international search report

(88) Date of publication of the international search report:
7 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/62227 A3

(54) Title: ANTICHOLINERGIC DRUG FORMULATIONS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

(57) Abstract: Formulations for the administration through pressurized metered dose aerosol inhalers containing an anticholinergic drug in solution in a hydrofluorocarbon propellant, a cosolvent and a low volatility component, and the use thereof in chronic obstructive pulmonary disease.

INTERNATIONAL SEARCH REPORT

Interr. Application No
PCT/EP 01/01833

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/12 A61K31/46

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 13262 A (JAGER PAUL D ;KONTNY MARK J (US); NAGEL JURGEN H (DE)) 23 June 1994 (1994-06-23) cited in the application the whole document tables 1,2 ---	1,2,5
A	WO 98 56349 A (BRAMBILLA GAETANO ;LEWIS DAVID (IT); VENTURA PAOLO (IT); GANDERTON) 17 December 1998 (1998-12-17) page 8, line 12 - line 19 page 11, line 13 -page 12, line 28 page 14, line 16 - line 22 page 15, line 6 - line 15 page 15, line 30 -page 16, line 7 claims; table 3 ---	3,4,6,7
A	---	1-7

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

3 September 2001

10/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

Intern	nal Application No
PCT/EP 01/01833	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	WO 00 30608 A (BRAMBILLA GAETANO ;LEWIS DAVID (IT); VENTURA PAOLO (IT); GANDERTON) 2 June 2000 (2000-06-02) page 4, line 26 -page 6, line 12 page 7, line 8 -page 8, line 21; claims 1,3-11; example 1; table 1 -----	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr.	nai Application No
PCT/EP 01/01833	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9413262	A 23-06-1994	AT 177941 T AU 680227 B AU 5740594 A AU 6048694 A BG 62382 B BG 99760 A BR 9307627 A CZ 9501490 A DE 69324161 D DE 69324161 T DK 673240 T EP 0673240 A ES 2129117 T FI 952842 A GB 2288978 A, B GR 3030529 T HK 1011620 A HU 72985 A JP 3009924 B JP 8509459 T LV 10911 A LV 10911 B NO 952269 A NZ 259192 A PL 309333 A SG 52459 A SK 76095 A WO 9413263 A US 6045778 A US 5676930 A US 5955058 A CN 1095265 A, B RU 2126248 C TW 403657 B ZA 9309195 A		15-04-1999 24-07-1997 04-07-1994 04-07-1994 29-10-1999 29-02-1996 15-06-1999 13-12-1995 29-04-1999 28-10-1999 11-10-1999 27-09-1995 01-06-1999 09-06-1995 08-11-1995 29-10-1999 20-04-2000 28-06-1996 14-02-2000 08-10-1996 20-12-1995 20-04-1996 08-06-1995 26-05-1997 02-10-1995 28-09-1998 08-01-1997 23-06-1994 04-04-2000 14-10-1997 21-09-1999 23-11-1994 20-02-1999 01-09-2000 08-06-1995
WO 9856349	A 17-12-1998	GB 2326334 A AU 729966 B AU 8626298 A BG 103221 A BR 9805993 A CN 1229355 T CZ 9900462 A EE 9900055 A EP 0920302 A HR 980317 A HU 0001339 A IT MI971798 A JP 2000516965 T NO 990594 A PL 331531 A SK 17699 A TR 9900288 T ZA 9805136 A		23-12-1998 15-02-2001 30-12-1998 30-09-1999 31-08-1999 22-09-1999 14-07-1999 16-08-1999 09-06-1999 30-04-1999 28-09-2000 28-01-1999 19-12-2000 13-04-1999 19-07-1999 12-07-1999 21-09-1999 07-01-1999
WO 0030608	A 02-06-2000	AU 1556300 A DE 29923839 U NO 20012516 A		13-06-2000 01-03-2001 23-07-2001